# Infliximab

Source: https://onco.cc/drugs/infliximab/  
OnCo record `infliximab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Infliximab is an anti-inflammatory drip used for Crohn's disease and arthritis. When checkpoint immunotherapy causes colitis that steroids do not control, it is the usual next step; it is avoided for immune hepatitis.

## Summary

The Remicade label covers Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. SITC 2021: if colitis does not respond to corticosteroids within 3 to 5 days, recurs on the taper, or is severely ulcerative at colonoscopy, "3 doses of infliximab (5 mg/kg) should be administered at 0, 2, and 6 weeks" (LE 1); people should be tested for hepatitis B, HIV and tuberculosis first without delaying the dose; and "Infliximab should not be used in patients with liver toxicity, given the risk for hepatotoxicity". SITC also names it for steroid-refractory nephritis and pneumonitis. The BLA was first approved on 24 August 1998.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-11
- Tags: supportive; generic; supportive-care-gaps-2026-11
- Brand: Remicade
- Modality: Monoclonal antibody (TNF blocker)
- Mechanism: A chimeric monoclonal antibody that binds and blocks tumour necrosis factor alpha.
- Approvals: US 1998: Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Infliximab
- US label (DailyMed): Remicade: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
- Brahmer et al., SITC clinical practice guideline on immune checkpoint inhibitor-related adverse events (J Immunother Cancer 2021): https://doi.org/10.1136/jitc-2021-002435

## Connected records

- drugs: [Mycophenolate mofetil](https://onco.cc/drugs/mycophenolate/), [Vedolizumab](https://onco.cc/drugs/vedolizumab/)
- terms: [Immune-mediated colitis and diarrhoea](https://onco.cc/terms/immune-colitis/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [Pneumonitis](https://onco.cc/terms/pneumonitis/)

---
JSON: https://onco.cc/api/v1/entities/infliximab.json